T. Rowe Price Associates’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $19.9M | Sell |
151,256
-1,720,984
| -92% | -$228M | ﹤0.01% | 1038 |
|
|
2025
Q4 | $266M | Sell |
1,872,240
-994,491
| -35% | -$144M | 0.03% | 385 |
|
|
2025
Q3 | $402M | Sell |
2,866,731
-219,726
| -7% | -$29.8M | 0.04% | 307 |
|
|
2025
Q2 | $388M | Buy |
3,086,457
+1,546,856
| +100% | +$177M | 0.04% | 304 |
|
|
2025
Q1 | $170M | Buy |
1,539,601
+49,088
| +3% | +$6.22M | 0.02% | 456 |
|
|
2024
Q4 | $203M | Sell |
1,490,513
-184,663
| -11% | -$22.8M | 0.02% | 425 |
|
|
2024
Q3 | $193M | Sell |
1,675,176
-123,672
| -7% | -$17M | 0.02% | 446 |
|
|
2024
Q2 | $248M | Sell |
1,798,848
-21,948
| -1% | -$3.01M | 0.03% | 378 |
|
|
2024
Q1 | $251M | Buy |
1,820,796
+343,847
| +23% | +$47M | 0.03% | 383 |
|
|
2023
Q4 | $195M | Buy |
1,476,949
+297,299
| +25% | +$34.2M | 0.03% | 424 |
|
|
2023
Q3 | $133M | Sell |
1,179,650
-150,178
| -11% | -$15.8M | 0.02% | 462 |
|
|
2023
Q2 | $125M | Sell |
1,329,828
-64,321
| -5% | -$6.28M | 0.02% | 488 |
|
|
2023
Q1 | $141M | Sell |
1,394,149
-31,141
| -2% | -$3.24M | 0.02% | 451 |
|
|
2022
Q4 | $170M | Sell |
1,425,290
-38,124
| -3% | -$4.47M | 0.03% | 401 |
|
|
2022
Q3 | $155M | Sell |
1,463,414
-2,492,873
| -63% | -$253M | 0.03% | 402 |
|
|
2022
Q2 | $386M | Sell |
3,956,287
-332,483
| -8% | -$30.7M | 0.05% | 338 |
|
|
2022
Q1 | $402M | Sell |
4,288,770
-70,875
| -2% | -$6.01M | 0.04% | 369 |
|
|
2021
Q4 | $371M | Sell |
4,359,645
-104,640
| -2% | -$9.63M | 0.03% | 406 |
|
|
2021
Q3 | $428M | Sell |
4,464,285
-564,974
| -11% | -$53.4M | 0.04% | 374 |
|
|
2021
Q2 | $489M | Sell |
5,029,259
-744,100
| -13% | -$71.3M | 0.05% | 339 |
|
|
2021
Q1 | $561M | Sell |
5,773,359
-498,371
| -8% | -$52.3M | 0.06% | 310 |
|
|
2020
Q4 | $601M | Sell |
6,271,730
-150,008
| -2% | -$14.5M | 0.06% | 297 |
|
|
2020
Q3 | $618M | Sell |
6,421,738
-257,855
| -4% | -$29.8M | 0.07% | 274 |
|
|
2020
Q2 | $815M | Buy |
6,679,593
+108,822
| +2% | +$12M | 0.1% | 206 |
|
|
2020
Q1 | $569M | Sell |
6,570,771
-720,526
| -10% | -$70.5M | 0.09% | 235 |
|
|
2019
Q4 | $784M | Buy |
7,291,297
+560,937
| +8% | +$58.7M | 0.1% | 212 |
|
|
2019
Q3 | $606M | Buy |
6,730,360
+3,348,591
| +99% | +$313M | 0.09% | 246 |
|
|
2019
Q2 | $286M | Sell |
3,381,769
-94,381
| -3% | -$7.75M | 0.04% | 383 |
|
|
2019
Q1 | $306M | Sell |
3,476,150
-533,213
| -13% | -$44.6M | 0.05% | 356 |
|
|
2018
Q4 | $286M | Sell |
4,009,363
-1,878,121
| -32% | -$180M | 0.05% | 340 |
|
|
2018
Q3 | $724M | Sell |
5,887,484
-42,823
| -0.7% | -$4.86M | 0.11% | 204 |
|
|
2018
Q2 | $583M | Sell |
5,930,307
-334,357
| -5% | -$29.9M | 0.09% | 224 |
|
|
2018
Q1 | $520M | Buy |
6,264,664
+33,634
| +0.5% | +$2.84M | 0.08% | 246 |
|
|
2017
Q4 | $483M | Sell |
6,231,030
-976,343
| -14% | -$66.6M | 0.08% | 264 |
|
|
2017
Q3 | $442M | Buy |
7,207,373
+41,489
| +0.6% | +$2.19M | 0.08% | 276 |
|
|
2017
Q2 | $330M | Buy |
7,165,884
+3,053,138
| +74% | +$148M | 0.06% | 325 |
|
|
2017
Q1 | $178M | Sell |
4,112,746
-1,867,417
| -31% | -$80M | 0.03% | 452 |
|
|
2016
Q4 | $231M | Sell |
5,980,163
-3,384,151
| -36% | -$153M | 0.05% | 394 |
|
|
2016
Q3 | $474M | Buy |
9,364,314
+169,460
| +2% | +$8.44M | 0.1% | 242 |
|
|
2016
Q2 | $418M | Sell |
9,194,854
-380,890
| -4% | -$17.5M | 0.09% | 246 |
|
|
2016
Q1 | $379M | Sell |
9,575,744
-57,943
| -0.6% | -$2.3M | 0.08% | 268 |
|
|
2015
Q4 | $545M | Buy |
9,633,687
+863,678
| +10% | +$43.9M | 0.11% | 195 |
|
|
2015
Q3 | $349M | Sell |
8,770,009
-1,023,730
| -10% | -$49.5M | 0.08% | 273 |
|
|
2015
Q2 | $468M | Sell |
9,793,739
-84,100
| -0.9% | -$3.57M | 0.1% | 237 |
|
|
2015
Q1 | $392M | Sell |
9,877,839
-191,400
| -2% | -$6.85M | 0.08% | 282 |
|
|
2014
Q4 | $225M | Buy |
10,069,239
+85,600
| +0.9% | +$1.62M | 0.05% | 401 |
|
|
2014
Q3 | $156M | Sell |
9,983,639
-271,600
| -3% | -$4.06M | 0.03% | 485 |
|
|
2014
Q2 | $152M | Sell |
10,255,239
-1,700
| -0% | -$24K | 0.03% | 510 |
|
|
2014
Q1 | $165M | Buy |
10,256,939
+945,000
| +10% | +$16.2M | 0.04% | 483 |
|
|
2013
Q4 | $87M | Sell |
9,311,939
-700,500
| -7% | -$6.84M | 0.02% | 655 |
|
|
2013
Q3 | $113M | Buy |
10,012,439
+2,143,580
| +27% | +$29.5M | 0.03% | 554 |
|
|
2013
Q2 | $105M | Buy |
+7,868,859
| New | +$96.7M | 0.03% | 561 |
|
Other funds holding NBIX
VPM
VCM
T. Rowe Price Associates's NBIX Position: Q1 2026 in Review
T. Rowe Price Associates reduced its Neurocrine Biosciences (NBIX) stake by 92% in Q1 2026, selling an estimated $228M and leaving 151,256 shares worth $19.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1038.
T. Rowe Price Associates first reported a position in NBIX in Q2 2013 and has held it in 52 quarters since. The position peaked at $815M in Q2 2020. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- T. Rowe Price Associates held 151,256 shares of Neurocrine Biosciences worth $19.9M as of Q1 2026.
- T. Rowe Price Associates sold 1,720,984 Neurocrine Biosciences shares in Q1 2026, an estimated $228M.
- Neurocrine Biosciences made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #1038 holding.
- T. Rowe Price Associates first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 52 quarters since.
- T. Rowe Price Associates's Neurocrine Biosciences position peaked at $815M in Q2 2020.
- 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.